AtaiBeckley stock has delivered a strong 121.4% return over the past three years, yet its low value score and an overvalued ...
Market speculation is building around a potential takeover of AtaiBeckley (NasdaqGM:ATAI) by a major U.S. pharmaceutical ...
AtaiBeckley's BPL-003 has aligned its research with the FDA's feedback and will proceed with a two-study Phase 3 trial. Read ...
AtaiBeckley (ATAI) is speculated to have received takeover interest. A large American pharmaceutical company may be circling ...
Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...
Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...
That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...
atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help ...
atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...
Atai Life Sciences (ATAI +7.81%), a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of ...
atai Life Sciences (NASDAQ:ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds. What Happened: The clinical-stage biotechnology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results